🇨🇭 Switzerland Overview
Medical cannabis treatment has been legal in Switzerland since 2011, when a regulatory change allowed patients to access medical cannabis after obtaining a specific exemption to do so from the country’s health regulator. In 2022, this system was updated, and an exemption is no longer required for a doctor to prescribe medical cannabis to a patient.
Despite the rule change in 2022, patient numbers in the country have not grown significantly in recent years. This is due to a number of factors, but chiefly the bureaucracy associated with treating patients, in particular with seeking reimbursement for treatment, which is granted on a case-by-case basis.
The Swiss medical market has always been supplied primarily by a small number of domestic producers, as well as imports of dronabinol from Germany. There are now more imports coming into the country from other countries, and domestic producers are trying to scale up to export to the German and UK markets. Overall levels of activity on both fronts are still relatively small.
Unlike most other medical cannabis markets, the Swiss market is dominated by extracts. There is currently an approximate 80/20 split in favour of extract in the proportion of products used in patient treatment. Click here for premium data packages, including pa tient population forecasts.
🇨🇭 Regulations
The most noteworthy amendment in the medical cannabis regulatory framework of Switzerland occurred in August 2022, as the country reclassified medical cannabis (flowers, resins, extracts, oils, tinctures for medical purposes) from a prohibited narcotic (Schedule D) to a controlled narcotic (Schedule A) in the Narcotics List Ordinance.
The change also included the removal of the prohibition in Art. 8 for cannabis for medical purposes in the Narcotics Act. Allowing medical cannabis to be covered by the same legal framework as other narcotic medicines, such as morphine.
The country also established a controlled framework for the cultivation, trade, distribution and dispensation of medical cannabis in which companies must obtain licences from Swissmedic for their relevant activity.
In terms of medical cannabis cultivation, Swissmedic assumes the role of the Cannabis Agency, and companies are bound to strict requirements and inspections to obtain a licence which is valid for 5 years.
🇨🇭 Patient Access
Who Can Prescribe?
Any licensed doctor in Switzerland can prescribe medical cannabis.
What are the treatable pathologies?
In Switzerland, cannabis can be prescribed for a broad range of conditions, although it is most commonly recommended for the following:
- Severe chronic pain
- Spasticity in multiple sclerosis or other neurological conditions
- Neuropathic pain
- Cancer-related pain
- Nausea and loss of appetite, particularly in chemotherapy patients
Reimbursement
Public Healthcare System (OKP)
In Switzerland, the coverage of medical cannabis under the country’s health insurance systems presents a complex landscape. While the compulsory health insurance (OKP) typically does not cover the cost of medical cannabis treatments, there are notable exceptions that can make these treatments accessible under certain conditions. Coverage for medical cannabis is considered in cases of hardship. This means that if a patient faces a potentially fatal disease or one that causes severe and chronic health impairments, and if no other effective and approved treatments are available, then the use of medical cannabis might be covered. For these exceptions to be made, several conditions must be met:
- The medical cannabis treatment must be expected to offer significant health improvements or stabilization that other treatments have not provided.
- It must be clear that other approved and effective treatment methods have been considered and ruled out, either due to ineffectiveness or unsuitability for the patient’s condition.
- The treating physician must formally request cost approval. This involves preparing a detailed justification that outlines the necessity of medical cannabis, supported by medical evidence and a comprehensive treatment plan.
Private Healthcare Insurance
Unlike the OKP, private health insurance in Switzerland might offer more flexibility regarding the coverage of treatments like medical cannabis. The specifics can vary significantly between different insurers and individual insurance plans. Some private plans may include coverage for alternative therapies, including medical cannabis, especially if these treatments can be shown to be cost-effective or particularly beneficial for the insured’s condition. Private health insurers may assess the inclusion of medical cannabis on a case-by-case basis, taking into account the medical necessity and potential benefits against the cost. The decision often involves an evaluation of the patient’s medical history and previous treatment outcomes.
Who Can Prescribe?
Any licensed doctor in Switzerland can prescribe medical cannabis.
What are the treatable pathologies?
In Switzerland, cannabis can be prescribed for a broad range of conditions, although it is most commonly recommended for the following:
- Severe chronic pain
- Spasticity in multiple sclerosis or other neurological conditions
- Neuropathic pain
- Cancer-related pain
- Nausea and loss of appetite, particularly in chemotherapy patients
Reimbursement
Public Healthcare System (OKP)
In Switzerland, the coverage of medical cannabis under the country’s health insurance systems presents a complex landscape. While the compulsory health insurance (OKP) typically does not cover the cost of medical cannabis treatments, there are notable exceptions that can make these treatments accessible under certain conditions. Coverage for medical cannabis is considered in cases of hardship. This means that if a patient faces a potentially fatal disease or one that causes severe and chronic health impairments, and if no other effective and approved treatments are available, then the use of medical cannabis might be covered. For these exceptions to be made, several conditions must be met:
- The medical cannabis treatment must be expected to offer significant health improvements or stabilization that other treatments have not provided.
- It must be clear that other approved and effective treatment methods have been considered and ruled out, either due to ineffectiveness or unsuitability for the patient’s condition.
- The treating physician must formally request cost approval. This involves preparing a detailed justification that outlines the necessity of medical cannabis, supported by medical evidence and a comprehensive treatment plan.
Private Healthcare Insurance
Unlike the OKP, private health insurance in Switzerland might offer more flexibility regarding the coverage of treatments like medical cannabis. The specifics can vary significantly between different insurers and individual insurance plans. Some private plans may include coverage for alternative therapies, including medical cannabis, especially if these treatments can be shown to be cost-effective or particularly beneficial for the insured’s condition. Private health insurers may assess the inclusion of medical cannabis on a case-by-case basis, taking into account the medical necessity and potential benefits against the cost. The decision often involves an evaluation of the patient’s medical history and previous treatment outcomes.
🇨🇭 Products & Prices
Switzerland has an unusually high number of products on the market for such a small patient base. However, a large number of these products are simply magistral recipes, rather than products stocked by pharmacies.
The majority of the products used in patient treatment are cultivated and processed in Switzerland.
